Autopsy report · NCT02672358

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

“Company Decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Non-Small-Cell Lung Cancer

Interventions

Dabrafenib; Trametinib

Participants

0

Trials that died the same way

• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (97% match in meaning)
• V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse
  “Company business decision” (92% match in meaning)
• A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
  “Corporate decision” (90% match in meaning)
• HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
  “Business decision” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.